Monograph
A10BJ06 - Semaglutide |
Propably not porphyrinogenic |
PNP |
Important Information
Side effects such as nausea, vomiting and loss of appetite may be potentially porphyrinogenic through reduction in carbohydrate intake. If used for weight management, carbohydrate intake must be kept at a sufficient level.
Side effects
Nausea and vomiting is reported as very common adverse reactions of semaglutid and these side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Semaglutide is a hormone analogue that is not metabolized by Cyp enzymes, and it is not an inducer or inhibitor of CYP.
Chemical description
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Therapeutic characteristics
Semaglutide is indicated in adults with type 2 diabetes mellitus to improve glycaemic control but is also used for weight management. It is administered once weekly as a subcutaneous injection, or as a daily oral dose.
Metabolism and pharmacokinetics
Semaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways (SPC).
Semaglutide is not expected to affect the cytochrome P450 system, and in vitro studies suggest that semaglutide has very low potential to inhibit or induce CYP enzymes (EMA). No CYP related interactions are listed in drug-drug interaction databases.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | DrugBank. (semaglutide). Accessed: (feb 2024)
|
|
| * | Government bodies | |
| 2. | European Public Assessment Report, Ozemic (Scientific discussion). European Medicines Agency (EMA). Accessible from: www.ema.europa.eu.
|
|
| * | Drug interaction databases | |
| 3. | Lexi-Interact, via UpToDate.
|
|
| 4. | Micromedex® 2.0 (online). Drug Interactions).
|
|
| 5. | The Danish Health and Medicines Authority. The drug interaction database.
|
|
| * | Summary of Product Characteristics | |
| 6. | The Electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Rybelsus.
|
|
| * | Other sources | |
| 7. | Interaction databases:
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy 
Ozempic · Rybelsus · Wegovy
© NAPOS 2025